Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2009 - 2026)

Regeneron Pharmaceuticals has reported Current Deferred Revenue for 18 years, with the latest figure at $636.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 2.73% year-over-year to $636.2 million; the trailing twelve-month figure through Mar 2026 stood at $636.2 million (up 2.73% YoY), and the FY2025 full-year result was $553.0 million, down 11.9% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $636.2 million, up from $553.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $636.2 million in Q1 2026, with the low at $381.1 million in Q2 2023.
• Average Current Deferred Revenue over 5 years is $527.1 million, with a median of $545.6 million recorded in 2025.
• Year-over-year, Current Deferred Revenue plunged 32.7% in 2023 and jumped 53.77% in 2024.
• Tracing REGN's Current Deferred Revenue over 5 years: stood at $477.9 million in 2022, then retreated by 3.98% to $458.9 million in 2023, then soared by 36.78% to $627.7 million in 2024, then retreated by 11.9% to $553.0 million in 2025, then grew by 15.05% to $636.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $636.2 million (Q1 2026), $553.0 million (Q4 2025), and $545.6 million (Q3 2025), per Business Quant data.

Peer Comparison